United Therapeutics CEO Martine Rothblatt disposes of 9,500 shares for $4.79 millionPUBT·1 day ago, 03:32 PMUTHR+2.10%
United Therapeutics seeks FDA priority review for Tyvaso label expansion in IPFPUBT·2 days ago, 06:00 AMUTHR+2.10%
United Therapeutics CEO Chair Martine Rothblatt disposes of 9,500 shares for $4.81 millionPUBT·Aug 14 at 03:48 PMUTHR+2.10%
Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics RivalryUnusual Whales·Aug 12 at 08:33 AMLQDA+1.35%UTHR+2.10%
United Therapeutics CEO Chairperson Martine Rothblatt disposes of 9,500 shares worth $5.03 millionPUBT·Aug 10 at 03:41 PMUTHR+2.10%
United Therapeutics CEO Martine Rothblatt disposes of 9,595 common shares worth $4.98 millionPUBT·Aug 6 at 03:35 PMUTHR+2.10%
Royal Bank Of Canada Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock PriceMarket Beat·Aug 6 at 01:18 PMUTHR+2.10%
United Therapeutics Q2 2026 earnings: Lower taxes lift EPS as revenue slipsTradingKey·Aug 5 at 05:50 AMUTHR+2.10%
UTHR: Q2 2026 revenue was $783M, with record Tyvaso DPI growth and strong pipeline progressQuartr·Aug 5 at 05:35 AMUTHR+2.10%
United Therap | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 783.3 MEarnings Watch·Aug 5 at 05:35 AMUTHR+2.10%
United Therapeutics Chairperson, CEO Martine Rothblatt reports disposal of 9,500 common shares for $4.9 millionPUBT·Aug 4 at 03:34 PMUTHR+2.10%
Amundi Sells 15,595 Shares of United Therapeutics Corporation $UTHRMarket Beat·Aug 2 at 02:04 AMUTHR+2.10%
Access Investment Management LLC Trims Stock Position in United Therapeutics Corporation $UTHRMarket Beat·Aug 1 at 02:52 AMUTHR+2.10%
